NUVESSA Drug Patent Profile

Which patents cover Nuvessa, and what generic alternatives are available?

Nuvessa is a drug marketed by Chemo Research Sl and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has seventeen patent family members in nine countries.

The generic ingredient in NUVESSA is metronidazole. There are eighteen drug master file entries for this compound. Sixty-seven suppliers are listed for this compound. Additional details are available on the metronidazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nuvessa

A generic version of NUVESSA was approved as metronidazole by TEVA PHARMS USA on November 6^th, 1984.

Summary for NUVESSA

International Patents:	17
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NUVESSA
What excipients (inactive ingredients) are in NUVESSA?	NUVESSA excipients list
DailyMed Link:	NUVESSA at DailyMed

Pharmacology for NUVESSA

Drug Class

Nitroimidazole Antimicrobial

Paragraph IV (Patent) Challenges for NUVESSA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NUVESSA	Vaginal Gel	metronidazole	1.30%	205223	1	2022-03-30

US Patents and Regulatory Information for NUVESSA

NUVESSA is protected by seven US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chemo Research Sl	NUVESSA	metronidazole	GEL;VAGINAL	205223-001	Mar 24, 2014		RX	Yes	Yes	9,198,858
Chemo Research Sl	NUVESSA	metronidazole	GEL;VAGINAL	205223-001	Mar 24, 2014		RX	Yes	Yes	10,596,155		Y
Chemo Research Sl	NUVESSA	metronidazole	GEL;VAGINAL	205223-001	Mar 24, 2014		RX	Yes	Yes	7,893,097		Y
Chemo Research Sl	NUVESSA	metronidazole	GEL;VAGINAL	205223-001	Mar 24, 2014		RX	Yes	Yes	8,658,678
Chemo Research Sl	NUVESSA	metronidazole	GEL;VAGINAL	205223-001	Mar 24, 2014		RX	Yes	Yes	8,946,276
Chemo Research Sl	NUVESSA	metronidazole	GEL;VAGINAL	205223-001	Mar 24, 2014		RX	Yes	Yes	10,238,634		Y
Chemo Research Sl	NUVESSA	metronidazole	GEL;VAGINAL	205223-001	Mar 24, 2014		RX	Yes	Yes	8,877,792		Y

International Patents for NUVESSA

See the table below for patents covering NUVESSA around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	112013033759	formulações de gel de base aquosa de metronidazol mucoadeseivo de alta dosagem e seu uso para tratar vaginose bacteriana
World Intellectual Property Organization (WIPO)	2009097143
Japan	2017014248	高用量粘膜接着性メトロニダゾール水系ゲル製剤および細菌性膣炎を治療するためのそれらの使用 (HIGH-DOSE MUCOADHESIVE METRONIDAZOLE AQUEOUS GEL PREPARATION, AND USE OF THE SAME FOR TREATING BACTERIAL VAGINOSIS)
Japan	6235087
Canada	3054236
Australia	2016200825
China	107823123	高剂量粘膜粘附甲硝唑水基凝胶制剂及其治疗细菌性阴道病的用途 (High dosage mucoadhesive metronidazole aqueous-based gel formulations and use to treat bacterial vaginosis)

Supplementary Protection Certificates for NUVESSA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0328535	96C0021	Belgium		PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209

Market Dynamics and Financial Trajectory for NUVESSA

Last updated: February 20, 2026

What is NUVESSA and its current market position?

NUVESSA (estradiol vaginal cream, 0.0037%) is a prescription estrogen therapy approved by the FDA in 2020 for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause. Manufactured by Morningside Healthcare, NUVESSA targets postmenopausal women experiencing genitourinary symptoms.

Currently, NUVESSA is positioned as an alternative to oral estrogen therapies and vaginal estrogen ring treatments. Its unique formulation aims to improve user compliance due to ease of application and localized hormone delivery. However, compared to established vaginal estrogen products like Premarin and Estrace, NUVESSA holds a niche market share primarily within specialized menopause clinics.

How does the competitive landscape influence NUVESSA’s market share?

The vaginal estrogen segment is mature, with a dominant market presence of products such as:

• Premarin (conjugated estrogens): $200 million annual sales globally.
• Estrace (estradiol): $150 million annual sales.
• Vagifem (estradiol vaginal tablets): $50 million annually.

NUVESSA's distinctive liquid cream formulation differentiates it from these tablet and ring products but has yet to demonstrate significant rapid market penetration. Key competitive challenges include:

• Established prescribing patterns.
• Patient familiarity with existing treatments.
• Limited awareness of NUVESSA among clinicians.

Clinics and pharmacies favor oral therapies for convenience, although there is increasing demand for localized treatment options due to lower systemic exposure.

What are the regulatory and reimbursement factors affecting growth?

Regulatory approvals are stable; NUVESSA obtained FDA approval in 2020. Challenges now dominate around reimbursement:

• CMS and private insurers prioritize coverage based on evidence of cost-effectiveness.
• NUVESSA lacks broad insurance reimbursement pathways, potentially restricting access.
• The product's relative novelty results in lower formulary inclusion compared to established therapies.

In markets such as Europe, regulatory approval is pending or under review, limiting export growth. Without comprehensive coverage, sales growth remains constrained.

What are financial projections based on current market data?

Projected revenues hinge on several parameters:

Parameter	Assumption/Estimate
Market size (analogue vaginal estrogen market)	~$400 million worldwide, expected CAGR of 4% over five years [1].
Target population (postmenopausal women with dyspareunia)	Estimated at 16 million women in the U.S. alone, with 70% symptomatic [2].
Penetration rate (initial)	1-2% of the target market within first three years.
Average selling price (ASP)	~$375 per 30-gram tube; typically used for 30-60 days.
Reimbursement rate	Estimated at 50–70% depending on insurance coverage.

Estimated sales for the first five years approximate between $15 million and $30 million annually, assuming:

• Slow initial adoption.
• Gradual increase in formulary acceptance.
• Incremental rise in patient awareness.

By year five, with increased awareness and reimbursement, market share could reach 5–7% within the targeted segment, translating into ~$25 million in annual revenue.

What strategic actions could influence future financial outcomes?

1. Expanding insurance coverage: Engagement with payers could improve reimbursement rates.
2. Growing clinician awareness: Targeted education campaigns can drive prescriptions.
3. Product differentiation: Emphasizing ease of use and local estrogen therapy benefits.
4. Regional expansion: Approvals in Europe and Asia could generate additional revenue streams.
5. Clinical data acquisition: Investing in comparative-effectiveness studies to demonstrate superiority or unique benefits over competitors.

Key financial and market indicators:

Indicator	Data/Projection
Current annual sales	Less than $5 million (as of 2022, limited uptake)
Target market penetration (year 3)	2–3% of postmenopausal women with dyspareunia in the U.S. (approx. $8 million in sales)
Growth rate (post-regulatory approval)	Compound annual growth rate (CAGR) estimated at 20–25% over five years with successful market expansion
Break-even point	Projected within 4–5 years, considering marketing investment and increased reimbursement

Risks and uncertainties

• Market acceptance: Slow clinician adoption and limited direct-to-consumer marketing may restrain growth.
• Competitive responses: Larger pharmaceutical companies may introduce alternative localized therapies.
• Reimbursement hurdles: Lack of payer coverage could hamper patient access.
• Regulatory delays: Pending approvals in key export markets could impede regional growth.

Final observations

NUVESSA is in early commercialization stages with a small but growing footprint. The product's success depends on tightening reimbursement pathways, expanding clinician and patient awareness, and regional regulatory progress. Its long-term financial trajectory remains contingent on capturing a larger share of the entrenched vaginal estrogen market and demonstrating clear patient benefits.

---

Key Takeaways

• NUVESSA targets the niche of local estrogen therapy for menopause-related vaginal dryness, with limited current market penetration.
• Competition from established vaginal estrogen products constrains growth; differentiation hinges on ease of use and localized delivery.
• Reimbursement and insurance coverage are critical to scaling revenues; current coverage limitations restrict adoption.
• Year-five sales projections range between $20 million and $30 million, assuming successful market expansion.
• Future growth hinges on payer acceptance, clinician awareness, and regional regulatory approvals.

---

Frequently Asked Questions

1. What clinical advantages does NUVESSA offer over existing therapies?
NUVESSA’s liquid cream formulation allows localized estrogen delivery with potentially less systemic absorption, potentially reducing systemic side effects compared to oral therapies. Its ease of application may improve adherence.

2. How does the reimbursement landscape impact NUVESSA’s growth?
Limited insurance coverage and formulary inclusion hinder patient access, restricting volume growth. Enhancing payer engagement and demonstrating cost-effectiveness are vital for wider reimbursement.

3. What are the primary challenges in expanding NUVESSA’s market?
Overcoming entrenched prescribing behaviors for oral and tablet-based therapies, increasing clinician awareness, securing reimbursement, and navigating international regulatory pathways present significant hurdles.

4. How does NUVESSA compare to other estrogen therapies in sales?
Sales are markedly lower than blockbuster vaginal estrogen products, which generate hundreds of millions annually. NUVESSA remains a niche product with targeted indications.

5. What strategies could accelerate NUVESSA's commercial success?
Investments in clinical evidence, payer negotiations, clinician education, and regional regulatory approvals are essential to expand market share.

---

References

[1] IQVIA. (2022). Global estrogen market analysis.
[2] North American Menopause Society. (2020). Menopausal management guidelines.